2nd March 2016
Cypralis appoints Dr Michael Peel as Chief Scientific Officer.
27th January 2016
Neurodegenerative diseases are defined as hereditary and sporadic conditions characterised by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral structures of the nervous system
7th December 2015
Ongar, UK, 7th December 2015 / Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has entered into a collaboration with Janssen Pharmaceuticals I
20th March 2015
Cypralis Ltd has spun out from Selcia Ltd to focus on discovering and developing novel medicines for acute and chronic degenerative diseases.